Cardiac cell-repair therapy

Clinical issues

Bernard J. Gersh, Robert D. Simari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The possibility that cardiac cell-repair therapy might become a clinical reality is a challenge worthy of the current state of technological and scientific expertise at the start of the 21st century. The success of preclinical and early clinical studies is a strong inducement to move ahead with larger clinical trials, but caution is warranted given our lack of understanding of the potential mechanisms by which cell-repair therapy exerts a benefit on ventricular function, perfusion, and infarct size, irrespective of the type of cell, method, site, and disease entity. There are multiple clinical, mechanistic, and safety questions requiring answers, and these will be forthcoming only if the design of clinical trials is carefully tailored to answer specific questions. These questions, in turn, will require the use of different and multiple end points, depending on the specific issue and study. Accordingly, this review addresses the limitations of current clinical studies, the design of future trials, and the concept of a hierarchical series of end points that might provide answers to a host of different questions. Clinical and basic scientists need to approach the next generation of trials in partnership.

Original languageEnglish (US)
JournalNature Clinical Practice Cardiovascular Medicine
Volume3
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2006

Fingerprint

Cell- and Tissue-Based Therapy
Clinical Trials
Ventricular Function
Cell Size
Perfusion
Safety
Clinical Studies

Keywords

  • Cardiac cell-repair
  • Clinical trials
  • Congestive heart failure
  • Myocardial infarction
  • Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiac cell-repair therapy : Clinical issues. / Gersh, Bernard J.; Simari, Robert D.

In: Nature Clinical Practice Cardiovascular Medicine, Vol. 3, No. SUPPL. 1, 03.2006.

Research output: Contribution to journalArticle

Gersh, Bernard J. ; Simari, Robert D. / Cardiac cell-repair therapy : Clinical issues. In: Nature Clinical Practice Cardiovascular Medicine. 2006 ; Vol. 3, No. SUPPL. 1.
@article{033fcc6f13aa4415bead15e666d084f1,
title = "Cardiac cell-repair therapy: Clinical issues",
abstract = "The possibility that cardiac cell-repair therapy might become a clinical reality is a challenge worthy of the current state of technological and scientific expertise at the start of the 21st century. The success of preclinical and early clinical studies is a strong inducement to move ahead with larger clinical trials, but caution is warranted given our lack of understanding of the potential mechanisms by which cell-repair therapy exerts a benefit on ventricular function, perfusion, and infarct size, irrespective of the type of cell, method, site, and disease entity. There are multiple clinical, mechanistic, and safety questions requiring answers, and these will be forthcoming only if the design of clinical trials is carefully tailored to answer specific questions. These questions, in turn, will require the use of different and multiple end points, depending on the specific issue and study. Accordingly, this review addresses the limitations of current clinical studies, the design of future trials, and the concept of a hierarchical series of end points that might provide answers to a host of different questions. Clinical and basic scientists need to approach the next generation of trials in partnership.",
keywords = "Cardiac cell-repair, Clinical trials, Congestive heart failure, Myocardial infarction, Therapy",
author = "Gersh, {Bernard J.} and Simari, {Robert D.}",
year = "2006",
month = "3",
doi = "10.1038/ncpcardio0400",
language = "English (US)",
volume = "3",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Cardiac cell-repair therapy

T2 - Clinical issues

AU - Gersh, Bernard J.

AU - Simari, Robert D.

PY - 2006/3

Y1 - 2006/3

N2 - The possibility that cardiac cell-repair therapy might become a clinical reality is a challenge worthy of the current state of technological and scientific expertise at the start of the 21st century. The success of preclinical and early clinical studies is a strong inducement to move ahead with larger clinical trials, but caution is warranted given our lack of understanding of the potential mechanisms by which cell-repair therapy exerts a benefit on ventricular function, perfusion, and infarct size, irrespective of the type of cell, method, site, and disease entity. There are multiple clinical, mechanistic, and safety questions requiring answers, and these will be forthcoming only if the design of clinical trials is carefully tailored to answer specific questions. These questions, in turn, will require the use of different and multiple end points, depending on the specific issue and study. Accordingly, this review addresses the limitations of current clinical studies, the design of future trials, and the concept of a hierarchical series of end points that might provide answers to a host of different questions. Clinical and basic scientists need to approach the next generation of trials in partnership.

AB - The possibility that cardiac cell-repair therapy might become a clinical reality is a challenge worthy of the current state of technological and scientific expertise at the start of the 21st century. The success of preclinical and early clinical studies is a strong inducement to move ahead with larger clinical trials, but caution is warranted given our lack of understanding of the potential mechanisms by which cell-repair therapy exerts a benefit on ventricular function, perfusion, and infarct size, irrespective of the type of cell, method, site, and disease entity. There are multiple clinical, mechanistic, and safety questions requiring answers, and these will be forthcoming only if the design of clinical trials is carefully tailored to answer specific questions. These questions, in turn, will require the use of different and multiple end points, depending on the specific issue and study. Accordingly, this review addresses the limitations of current clinical studies, the design of future trials, and the concept of a hierarchical series of end points that might provide answers to a host of different questions. Clinical and basic scientists need to approach the next generation of trials in partnership.

KW - Cardiac cell-repair

KW - Clinical trials

KW - Congestive heart failure

KW - Myocardial infarction

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=31444446711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444446711&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio0400

DO - 10.1038/ncpcardio0400

M3 - Article

VL - 3

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - SUPPL. 1

ER -